Literature DB >> 11064349

Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy for maxillary sinus carcinoma.

H Nishino1, M Miyata, M Morita, K Ishikawa, T Kanazawa, K Ichimura.   

Abstract

BACKGROUND: Current goals for the treatment of carcinoma of the maxillary sinus include the preservation of vision, ability to eat, ability to communicate, and appearance as well as cure.
METHODS: Seventy-five Japanese patients who presented with maxillary sinus carcinoma between 1979 and 1997 were analyzed retrospectively. There were 48 males and 27 females with a median age of 62 years. The mean follow-up period was 73 months. All patients underwent multimodality therapy including surgery through a sublabial incision, radiotherapy, and regional chemotherapy. The regional lymph nodes were treated only in those patients with cervical lymph node involvement.
RESULTS: The 5-year and 10-year overall survival rates were 76% and 66%, respectively. In 65 patients with squamous cell carcinoma, the 5-year and 10-year overall survival rates were 77% and 66%, respectively. All 23 patients with orbital involvement retained the orbital contents and 17 patients demonstrated adequate ocular function. There was no disease recurrence reported among patients with involvement of the foramen rotundum or the foramen ovale, whereas two of the three patients with invasion of the foramen lacerum developed disease recurrence. There were 12 complications in 12 patients, including double vision (4 patients), cataracts (3 patients), trismus (4 patients), and fistula formation (1 patient).
CONCLUSIONS: Control of the primary tumor site is important in the curative treatment of patients with maxillary sinus carcinoma. Combined therapy with conservative surgery, radiotherapy, and regional chemotherapy appears to be an effective method for local control and the preservation of ocular function. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064349     DOI: 10.1002/1097-0142(20001101)89:9<1925::aid-cncr8>3.3.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Clinical and microdissection genotyping analyses of the effect of intra-arterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma.

Authors:  David T Tse
Journal:  Trans Am Ophthalmol Soc       Date:  2005

2.  The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.

Authors:  L Madison Michael; Jeffrey M Sorenson; Sandeep Samant; Jon H Robertson
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

Review 3.  The skull base, paranasal sinuses, and related malignancies.

Authors:  Chad A Zender; Guy J Petruzzelli
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

4.  Galanin receptor subtype 2 suppresses cell proliferation and induces apoptosis in p53 mutant head and neck cancer cells.

Authors:  Takeharu Kanazawa; Pavan K Kommareddi; Toshihide Iwashita; Bhavna Kumar; Kiyoshi Misawa; Yuki Misawa; Ilwhan Jang; Thankam S Nair; Yukiko Iino; Thomas E Carey
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

5.  Clonal evolution of a case of treatment refractory maxillary sinus carcinoma.

Authors:  Shilpi Arora; Ronald L Korn; Elizabeth Lenkiewicz; Irene Cherni; Thomas G Beach; Galen Hostetter; Michael T Barrett; Glen J Weiss
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

6.  Proton therapy for non-squamous cell carcinoma of the head and neck: planning comparison and toxicity.

Authors:  Hiromitsu Iwata; Toshiyuki Toshito; Kensuke Hayashi; Maho Yamada; Chihiro Omachi; Koichiro Nakajima; Yukiko Hattori; Shingo Hashimoto; Yo Kuroda; Yoshihide Okumura; Jun-Etsu Mizoe; Hiroyuki Ogino; Yuta Shibamoto
Journal:  J Radiat Res       Date:  2019-10-23       Impact factor: 2.724

7.  A Novel LncRNA, AC091729.7 Promotes Sinonasal Squamous Cell Carcinomas Proliferation and Invasion Through Binding SRSF2.

Authors:  Boyu Yu; Linmei Qu; Tianyi Wu; Bingrui Yan; Xuan Kan; Xuehui Zhao; Like Yang; Yushan Li; Ming Liu; Linli Tian; Yanan Sun; Qiuying Li
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.